- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Heidelberg Pharma AG (HPHA)
Heidelberg Pharma AG stock price live, this page displays ETR HPHA stock exchange data. View the HPHA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Heidelberg Pharma AG real time stock price chart below.
What Is the Heidelberg Pharma AG Stock Price Today?
The Heidelberg Pharma AG stock price today is 2.930.
What Is the Stock Symbol for Heidelberg Pharma AG?
The stock symbol for Heidelberg Pharma AG is "HPHA."
What Stock Exchange Does Heidelberg Pharma AG Trade On?
Heidelberg Pharma AG is listed and trades on the Xetra stock exchange.
Is Heidelberg Pharma AG a Good Stock to Buy?
Determining whether Heidelberg Pharma AG—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the HPHA quote. (ISIN: DE000A11QVV0)
What Is the Heidelberg Pharma AG Stock Price Today?
The Heidelberg Pharma AG stock price today is 2.930.
What Is the Stock Symbol for Heidelberg Pharma AG?
The stock symbol for Heidelberg Pharma AG is "HPHA."
What Stock Exchange Does Heidelberg Pharma AG Trade On?
Heidelberg Pharma AG is listed and trades on the Xetra stock exchange.
Is Heidelberg Pharma AG a Good Stock to Buy?
Determining whether Heidelberg Pharma AG—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the HPHA quote. (ISIN: DE000A11QVV0)
2.930
-0.020(-0.68%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.850
2.930
52 wk Range
2.200
5.360
HPHA is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.8502.930
52 wk Range
2.2005.360
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
HPHA Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
6.750
Upside
+130.38%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, the United States, and internationally. Its lead product candidates include HDP-101, an anti-BCMA antibody, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. The company develops HDP-102, an antibody and the compound Amanitin, which has completed preclinical development for the treatment of non-Hodgkin lymphoma; HDP-103, a proprietary ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for the treatment of gastrointestinal tumors; HDP-201 for the treatment of colorectal cancer; and TAK-ATAC for the treatment of oncology. It also develops TLX250-CDx, a diagnostic antibody for kidney cancer that is in Phase III trials, as well as for the treatment of bladder cancer. In addition, the company develops TLX250 (girentuximab), a therapeutic antibody, which is in Phase II study for the treatment of kidney cancer; and RHB-107, an orally serine protease inhibitor that is in Phase II study to treat COVID-19. It has licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. for the development and commercialization rights for HDP-101 and HDP-103 in Asia. The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is headquartered in Ladenburg, Germany.
Heidelberg Pharma AG Earnings Call Summary for Q4/2025
- Heidelberg Pharma reported Q4 2025 net loss of EUR 42.3M with EPS of -0.91 EUR; revenue fell 64% YoY to $3.55M amid strategic restructuring.
- R&D expenses surged 77.5% to EUR 38.7M as company refocused on lead program HDP-101; operating costs jumped 50.3% to EUR 49.0M year-over-year.
- Dr. Dongzhou Jeffery Liu appointed as new CEO; company extended cash runway to mid-2027 through non-dilutive financing and cost optimization.
- HDP-101 clinical trials show promising results with interim readouts expected mid-2026; stock rose 21% YTD despite financial challenges.
- Company maintains strong liquidity with 5.85 current ratio and more cash than debt, though faces risks from high burn rate and trial outcome dependency.
Last Updated: 03/26/2026, 10:20 PM
Read Full TranscriptCompare HPHA to Peers and Sector
Metrics to compare | HPHA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipHPHAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.3x | −1.2x | −0.4x | |
PEG Ratio | 0.03 | −0.01 | 0.00 | |
Price/Book | −12.6x | 0.9x | 2.6x | |
Price / LTM Sales | 19.9x | 4.8x | 3.1x | |
Upside (Analyst Target) | 128.8% | 122.4% | 58.8% | |
Fair Value Upside | Unlock | 16.4% | 9.2% | Unlock |
Analyst Ratings
2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 6.750
(+130.38% Upside)
Earnings
Latest Release
Mar 25, 2026
EPS / Forecast
-0.46 / --
Revenue / Forecast
5.5M / --
People Also Watch
FAQ
What Is the Heidelberg Pharma AG (HPHA) Stock Price Today?
The Heidelberg Pharma AG stock price today is 2.930 EUR.
What Stock Exchange Does Heidelberg Pharma AG Trade On?
Heidelberg Pharma AG is listed and trades on the Frankfurt Stock Exchange.
What Is the Stock Symbol for Heidelberg Pharma AG?
The stock symbol for Heidelberg Pharma AG is "HPHA."
What Is the Heidelberg Pharma AG Market Cap?
As of today, Heidelberg Pharma AG market cap is 137.080M EUR.
What Is Heidelberg Pharma AG's Earnings Per Share (TTM)?
The Heidelberg Pharma AG EPS (TTM) is -0.906.
When Is the Next Heidelberg Pharma AG Earnings Date?
Heidelberg Pharma AG will release its next earnings report on Apr 29, 2026.
From a Technical Analysis Perspective, Is HPHA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Heidelberg Pharma AG Stock Split?
Heidelberg Pharma AG has split 9 times.
How Many Employees Does Heidelberg Pharma AG Have?
Heidelberg Pharma AG has 114 employees.
What is the current trading status of Heidelberg Pharma AG (HPHA)?
As of Mar 31, 2026, Heidelberg Pharma AG (HPHA) is trading at a price of 2.930 EUR, with a previous close of 2.950 EUR. The stock has fluctuated within a day range of 2.850 EUR to 2.930 EUR, while its 52-week range spans from 2.200 EUR to 5.360 EUR.
What Is Heidelberg Pharma AG (HPHA) Price Target According to Analysts?
The average 12-month price target for Heidelberg Pharma AG is 6.750 EUR, with a high estimate of 8 EUR and a low estimate of 5.5 EUR. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +130.38% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.